Skip to main content
SpringerLink
Log in

Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Summary

Ductal carcinomain situ (intraductal carcinoma) of the breast is a commonly recognized and curable clinical entity. Patients with intraductal carcinoma are at risk to develop invasive breast cancer presumably due to a transition from the noninvasive to the invasive phase of growth. Primary breast malignancies commonly display bothin situ and invasive phases of growth in the same tumor. In the current study, DNA content and alterations in the erbB-2 (HER-2/neu) oncogene product were examined simultaneously in both growth phases of primary breast cancers by image analysis. DNA content in the intraductal and invasive components of primary breast cancers were virtually identical (r = 0.979, p < 0.001). Quantitative image analysis was used to measure erbB-2 expression and categories of expression were related to copy number of the erbB-2 gene. Expression of erbB-2 was similar in both growth phases and implies identity of the erbB-2 genotype. The identity of DNA content suggests that the noninvasive and invasive phases within a single breast cancer are highly related. It is likely that erbB-2 gene number remains the same during progression from intraductal to invasive disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Schnitt SJ, Silen W, Sadowsky NL, Connolly JL, Harris JR: Ductal carcinomain situ (intraductal carcinoma) of the breast. N Engl J Med 318: 898–903, 1988

    Google Scholar 

  2. Ashikari R, Huvos AG, Snyder RE: Prospective study of non-infiltrating carcinoma of the breast. Cancer 39: 435–439, 1977

    Google Scholar 

  3. Sunshine JA, Moseley HS, Fletcher WS, Krippaehne WW: Breast carcinomain situ: A retrospective review of 112 cases with a minimum 10 year follow-up. Am J Surg 150: 44–50, 1985

    Google Scholar 

  4. Gallager HS, Martin JE: The study of mammary carcinoma by mammography and a whole organ sectioning - early observations. Cancer 23: 855–863, 1969

    Google Scholar 

  5. Gallagher WJ, Koerner FC, Wood WC: Treatment of intraductal carcinoma with limited surgery: Long-term follow-up. J Clin Oncol 7: 376–380, 1989

    Google Scholar 

  6. Page DL, Dupont WD, Rogers LW, Landenberger M: Intraductal carcinoma of the breast: Follow-up after biopsy only. Cancer 49: 751–758, 1982

    Google Scholar 

  7. Betsill WL, Rosen PP, Lieberman PH, Robbins GF: Intraductal carcinoma: Long-term follow-up after treatment by biopsy alone. JAMA 239: 1863–1867, 1978

    Google Scholar 

  8. Silverstein MJ, Waisman JR, Gamagami P, Gierson ED, Colburn WJ, Rosser RJ, Gordon PS, Lewinsky BS, Fingerhut A: Intraductal carcinoma of the breast (208 cases): Clinical factors influencing treatment choice. Cancer 66: 102–108, 1990

    Google Scholar 

  9. Schechter AL, Stern DF, Vaidyanathan L, Decker SJ, Drebin JA, Greene MI, Weinberg RA: Theneu oncogene: anerb-B-related gene encoding a 185,000-Mr tumor antigen. Nature 312: 513–516, 1984

    Google Scholar 

  10. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T, Toyoshima K: Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319: 230–234, 1986

    Google Scholar 

  11. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244: 707–712, 1989

    Google Scholar 

  12. Press MF, Jones LA, Godolphin W, Edwards CL, Slamon DJ: HER-2/neu oncogene amplification and expression in breast and ovarian cancers. Prog Clin Biol Res 354A: 209–221, 1990

    Google Scholar 

  13. Lacroix H, Iglehart JD, Skinner MA, Kraus MH: Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases. Oncogene 4: 145–151, 1989

    Google Scholar 

  14. Iglehart JD, Kraus MH, Langton BC, Huper G, Kerns B-J, Marks JR: Increased erbB-2 gene copies and expression in multiple stages of breast cancer. Cancer Res 50: 6701–6707, 1990

    Google Scholar 

  15. van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R: Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinomain situ and limited prognostic value in stage II breast cancer. N Engl J Med 319: 1239–1245, 1988

    Google Scholar 

  16. Borg A, Linell F, Idvall I, Johansson S, Sigurdsson H, Ferno M, Killander D: HER2/neu amplification and comedo type breast carcinoma. Lancet 1: 1268–1269, 1989

    Google Scholar 

  17. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA: Immunohistochemical distribution of c-erbB-2 inin situ breast carcinoma - a detailed morphological analysis. J Pathol 161: 7–14, 1990

    Google Scholar 

  18. Lilleng R, Hagmar BM, Nesland JM: C-erbB-2 protein and neuroendocrine expression in intraductal carcinomas of the breast. Mod Pathol 5: 41–47, 1992

    Google Scholar 

  19. Schimmelpenning H, Eriksson ET, Pallis L, Skoog L, Cedermark B, Auer GU: Immunohistochemical c-erbB-2 protooncogene expression and nuclear DNA content in human mammary carcinomain situ. Am J Clin Pathol 97 (Suppl 1): S48-S52, 1992

    Google Scholar 

  20. Barnes DM, Bartkova J, Camplejohn RS, Gullick WJ, Smith PJ, Millis RR: Overexpression of the c-erbB-2 oncoprotein: Why does this occur more frequently in ductal carcinomain situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer 28: 644–648, 1992

    Google Scholar 

  21. Liu E, Thor A, He M, Barcos M, Ljung B-M, Benz C: The HER2 (c-erbB-2) oncogene is frequently amplified inin situ carcinomas of the breast. Oncogene 7: 1027–1032, 1992

    Google Scholar 

  22. Somerville JE, Clarke LA, Biggard JD: c-erbB-2 overex-pression and histological type ofin situ and invasive breast carcinoma. J Clin Path 45: 16–20, 1992

    Google Scholar 

  23. Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Groner B, Hynes NE: Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 48: 1238–1243, 1988

    Google Scholar 

  24. Bacus SS, Bacus JW, Slamon DJ, Press MF: HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer. Arch Pathol Lab Med 114: 164–169, 1990

    Google Scholar 

  25. Kraus MH, Popescu NC, Amsbaugh SC, King CR: Overexpression of the EGF receptor-related proto-oncogene erbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6: 605–610, 1987

    Google Scholar 

  26. Teplitz RL, Butler BB, Tesluk H, Min BH, Russell LA, Jensen HM, Hill LR: Quantitative DNA patterns in human preneoplastic breast lesions. Anal Quant Cytol Histol 12: 98–102, 1990

    Google Scholar 

  27. Carpenter R, Gibbs N, Matthews J, Cooke T: Importance of cellular DNA content in pre-malignant breast disease and pre-invasive carcinoma of the female breast. Br J Surg 74: 905–906, 1987

    Google Scholar 

  28. Davidoff AM, Kerns B-J, Iglehart JD, Marks JR: Maintenance of p53 alterations throughout stages of breast cancer progression. Cancer Res 51: 2605–2610, 1991

    Google Scholar 

  29. Pence JC, Kizilbash AM, Kerns B-J, Marks JR, Iglehart JD: Proliferation index in various stages of breast cancer determined by Ki-67 immunostaining. J Surg Oncol 48: 11–20, 1991

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery and Cell Biology, Duke University Medical Center, Box 3873, 27710, Durham, NC, USA

    J. Dirk Iglehart, Gudrun Huper & Jeffrey R. Marks

  2. Departments of Cell Biology, Duke University Medical Center, 27710, Durham, NC, USA

    J. Dirk Iglehart

  3. Departments of Pathology, Duke University Medical Center, 27710, Durham, NC, USA

    Billie-Jo Kerns

Authors
  1. J. Dirk Iglehart
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Billie-Jo Kerns
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gudrun Huper
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jeffrey R. Marks
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Iglehart, J.D., Kerns, BJ., Huper, G. et al. Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer. Breast Cancer Res Tr 34, 253–263 (1995). https://doi.org/10.1007/BF00689717

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00689717

Key words

Search

Navigation